The feeling of visiting the pharmaceutical factory
Release time:
2020-09-11
Pharmaceutical Factory Visit Feelings
7# On March 10 , the pharmaceutical company held a thematic training on "How to Write Press Release " and led the correspondent to visit the pharmaceutical factory. 2 years later, I returned to this "familiar battlefield " , thinking of the work scene of the workshop site QA and the craftsman in those days: watching the key positions to see the personnel operation process, following the workshop master to learn the post operation skills, and shuttling between the workshop and the central control laboratory to deliver samples every day, review batch production record ... The sense of urgency that counts against the clock, the frustration of lack of expertise and skills, always forces yourself to seek progress. In the pharmaceutical factory after the integration of
, the QAteam is reorganized. Although the personnel are young, they have ideas and are steadfast and willing to work. The safety and environmental protection management of the factory has been strengthened. Checkpoints and entrance guards have been set up at the entrance of the explosion-proof area. Non-factory personnel are not allowed to enter the factory without safety training, safety equipment and authorization from the factory leaders. The whole process of numerical control is implemented for sewage treatment and discharge, waste gas collection and spray incineration, rainwater discharge and other links, which is convenient for data traceability, and remote monitoring of the operation process is enabled. Managers can also check and supervision in real time; the factory has implemented internal control standardization, added some visual image publicity elements, and pasted positive energy slogans on the walls of the workshop office corridor to enhance the cohesion and centripetal force of the production team. Boldly set up a youth management team in the workshop, increase the training of youth teams in key positions in the workshop, and use the model of "old with new, strong with weak " , arrange a group of young people with ideas, innovation, and solid professional knowledge and skills to reasonable positions. These are all the changes in the pharmaceutical factory that I have seen and learned during this visit. Watching these changes also made me feel a lot.
Quality is the life of an enterprise. As a quality management personnel, I think whether it is a production enterprise or an operating enterprise, it can form an internal quality management system of the enterprise according to the 5key elements of personnel, equipment, materials, documents and environment, and carry out compliant production and business activities according to the system requirements and internal control standards. The production department strictly adheres to the quality control, makes efforts on these key elements, and supervises the implementation department in detail to ensure the quality compliance of the products. In the retail link of the business department, we have the most contact with patients. Now the complaints of patients have shifted from the price to the quality of the products. In addition to the appearance, the quality complaints are the use effect of drugs. In addition to the daily quality checks of drug administration and medical insurance, retail chain departments will encounter "alternative supervision " of "unannounced visits and anti-counterfeiting " personnel from time to time. If the inspection results of the latter are exposed to the media or the Internet, it will be for a retail pharmacy or even the entire operating enterprise, there will be threats ranging from small to large numbers of loyal buyers to "shutdown " . Therefore, we must always stay awake, do not step on the red line, do not touch the bottom line, avoid behavioral activities that can cause hidden dangers, and ensure the healthy and sustainable development of enterprises.
In strict quality at the same time, but also further innovation. In the development process of Jianfeng Group, we saw the boldness and courage of "dare to be the first and dare to be the first " from Du Zihong, the former head of Jianfeng Group. He led Jianfeng people to turn a small cement factory into the first listed company in China's cement industry. Since the current chairman Jiang Xiaomeng took office, the group has always adjusted the company's industrial structure, established the market with quality and brand, and strived to be the "leader " in the professional field, centering on the strategic idea of "cooperation and innovation to strengthen the main business, standardizing science and seeking development " . Over the years, Jianfeng Pharmaceutical has implemented the intellectual property policy of "intellectual property rights help enterprise development, scientific and technological innovation creates a century-old peak " , and actively cooperated with China University of Science and Technology, Zhejiang University of Technology, Sichuan Institute of Antibiotic Industry and other units to jointly build a scientific research innovation platform integrating "production, learning and research " , according to the development direction and market positioning of the group company, we have actively carried out scientific research and achieved fruitful results.
In addition to technological innovation, we also need innovation in management mode. First of all, managers should "down-to-earth " , often go to the grass-roots level, listen more to public opinion, solve people's worries, and tap skilled talents. Set an example, learn more and ask more, listen more and do more, master new ideas and skills in a timely manner, and solve problems in key steps in a timely manner. Secondly, enterprises should strengthen the training of talents in professional fields, carry out more lectures and training in professional fields, and expand the talent team. At the same time, enterprises should also carry forward the positive patriotic spirit internally, infiltrate the positive energy into the managers of each class and the employees of each department in a horizontal and vertical way, so as to enhance the employees' sense of belonging, mission and responsibility. (Lang Minxiao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31